Loading...
Docoh

TG Therapeutics (TGTX)

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.

Company profile

Ticker
TGTX
Exchange
CEO
Michael Weiss
Employees
Incorporated
Location
Fiscal year end
Former names
ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC
SEC CIK
Subsidiaries
Ariston Pharmaceuticals, Inc. • TG Biologics, Inc. • TG Therapeutics AUS Pty Ltd ...
IRS number
363898269

TGTX stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 May 22
12 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 186.94M 186.94M 186.94M 186.94M 186.94M 186.94M
Cash burn (monthly) 37.74M 23.82M 22.29M 26.87M 22.9M 23.58M
Cash used (since last report) 166.84M 105.31M 98.55M 118.79M 101.23M 104.25M
Cash remaining 20.11M 81.63M 88.39M 68.15M 85.71M 82.69M
Runway (months of cash) 0.5 3.4 4.0 2.5 3.7 3.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
20 Jul 22 Charney Laurence N Common Stock Grant Acquire A No No 0 43,732 0 264,729
20 Jul 22 Echelard Yann Common Stock Grant Acquire A No No 0 43,732 0 192,848
20 Jul 22 Sagar Lonial Common Stock Grant Acquire A No No 0 43,732 0 128,732
20 Jul 22 Daniel Hume Common Stock Grant Acquire A No No 0 43,732 0 198,239
20 Jul 22 Kenneth Hoberman Common Stock Grant Acquire A No No 0 43,732 0 222,685
13F holders Current Prev Q Change
Total holders 185 197 -6.1%
Opened positions 33 31 +6.5%
Closed positions 45 57 -21.1%
Increased positions 73 63 +15.9%
Reduced positions 46 62 -25.8%
13F shares Current Prev Q Change
Total value 1.05B 4.04B -74.0%
Total shares 102.63M 102.87M -0.2%
Total puts 1.51M 1.88M -19.7%
Total calls 2.09M 2.39M -12.5%
Total put/call ratio 0.7 0.8 -8.2%
Largest owners Shares Value Change
FMR 20.33M $193.33M -1.9%
Vanguard 12.13M $115.37M +0.3%
STT State Street 9.63M $91.57M +65.3%
BLK Blackrock 8.94M $84.98M +0.4%
Maverick Capital 6.68M $63.51M +10.7%
Wellington Management 4.02M $38.24M -5.4%
LFB Biotechnologies S.A.S.U. 2.61M $36.48M 0.0%
683 Capital Management 2.6M $24.72M +115.3%
Geode Capital Management 2.19M $20.81M -5.3%
Millennium Management 2.18M $20.7M +305.8%
Largest transactions Shares Bought/sold Change
Capital World Investors 0 -4.17M EXIT
STT State Street 9.63M +3.8M +65.3%
Ra Capital Management 0 -2.21M EXIT
Millennium Management 2.18M +1.64M +305.8%
683 Capital Management 2.6M +1.39M +115.3%
IVZ Invesco 330.46K -1.32M -80.0%
Pictet Asset Management 1.17M -1.22M -51.1%
Lion Point Capital 0 -1.16M EXIT
Antara Capital 1.03M +1.03M NEW
Citadel Advisors 1.08M +1.03M +2385.9%

Financial report summary

?
Management Discussion
  • Product revenue, net. Product revenue, net for the three months ended March 31, 2022 was $2.0 million compared to $0.8 million for the three months ended March 31, 2021. Product revenue, net consisted of net product sales of UKONIQ in the United States. In February 2021, we began commercial sales of UKONIQ within the U.S. following FDA approval. The $1.2 million increase was primarily driven by an increase in product shipments for UKONIQ as a result of greater market penetration. The increase in product shipments is partially offset by the recording of an additional allowance for sales returns in the first quarter of 2022 due to the anticipated increase in returns resulting from the voluntary withdrawal of UKONIQ from the U.S. market announced on April 15, 2022. Any product sales subsequent to the voluntary withdrawal are limited to existing patients that elect to remain on treatment and no shipments for new prescriptions are allowed. Therefore, it is expected product revenue, net will decline significantly throughout 2022 as a result of the voluntary market withdrawal of UKONIQ.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Good
New words: addtion, amplifying, anniversary, anti, ASC, Canada, canceled, Carolina, Chairman, check, convened, death, dismantle, driven, electronic, epitope, extinguishment, fashion, foreseen, France, gather, geopolitical, Georgia, Germany, glycoengineered, hoc, host, HR, imbalance, immunology, Interbank, invaded, invasion, Lender, military, NC, neighboring, North, notified, ODAC, OS, outdated, overarching, partake, path, paused, penalty, penetration, Poland, prompt, refinance, reinstated, reset, retention, retirement, Russia, Russian, Samsung, Slovakia, streamlining, SWIFT, Ukraine, undermining, unrestricted, vi, Vice, west, withdrawn, withdrew
Removed: AbbVie, acalabrutinib, account, accrue, achieved, adjustment, administer, advancing, AEs, AKS, allocated, allocating, ALT, analyst, annum, antigen, ASH, AST, AstraZeneca, ASU, authoritative, axicabtagene, Bayer, begin, bispecific, Brexit, BTK, budgetary, build, buying, calculate, calculating, capitalized, casein, channel, Checkpoint, chimeric, ciloleucel, closely, CMO, cohort, collectability, comprising, computation, Concurrently, consist, constraint, copanlisib, core, Cornell, CR, customary, damaged, delta, dependence, depict, deplete, depression, detected, display, distancing, DLBCL, drastically, duvelisib, earned, ending, enhancement, epidemic, Epizyme, epsilon, error, evolved, exacerbated, exceed, expired, explicitly, exploratory, explore, extranodal, FASB, feasible, filer, focusing, forecasted, formally, frame, Furman, generation, generically, Gilead, globe, goodwill, Gribben, hedging, heightening, hematological, Hematology, Hengrui, ibrutinib, idelalisib, immunotherapy, impairment, inclusion, inclusive, indexed, instability, integrated, interaction, interactive, intraperiod, Janssen, Japan, Jiangsu, John, language, launched, left, lenalidomide, lien, macroeconomic, MCL, Medicine, multicenter, NaN, NCCN, nodal, Novimmune, ocrelizumab, ODD, ofatumumab, opportunistic, optimal, ORR, owe, paydown, performing, persist, pharmacologic, pharmacy, phosphoinositide, prioritized, professional, promised, promote, rash, ratably, realizable, receptor, recession, recognize, recognizing, reflect, regularly, remained, remote, remotely, requesting, requirement, resume, returned, reversal, Richard, rituximab, robust, Roche, satisfied, scalable, Senate, settled, shipment, Simplifying, slowdown, specialty, splenic, spreading, Squibb, step, suitable, sum, supported, surge, targeting, tazemetostat, timeline, today, Topic, tranche, Tricare, triple, Tyrosine, underinsured, unexpectedly, uninsured, unit, variant, venetoclax, Verastem, vesting, virtual, virtually, Weill, worked, workforce, Wuhan

Patents

Utility
Triple Combination to Treat B-cell Malignancies
12 May 22
Methods for treating B-cell malignancies are provided comprising administering a triple combination of agents, comprising: (i) a PI3K-delta selective inhibitor (e.g., umbralisib); (ii) an anti-CD20 antibody (e.g., ublituximab); and (iii) the Bruton's tyrosine kinase (BTK) inhibitor TG-1701.
Utility
Combination of ANTI-CD20 Antibody, P13 Kinase-delta Selective Inhibitor, and BTK Inhibitor to Treat B-cell Proliferative Disorders
10 Jun 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Utility
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
6 Apr 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Utility
Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor
14 Oct 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders.
Utility
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
3 Aug 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes.